The BCL2 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BCL2 gene in the human HAP1 cell line. This heterogeneous pool of edited cells carries diverse loss-of-function mutations, providing a robust and reproducible model for investigating BCL2-dependent apoptosis regulation without the need for single-cell cloning.
The HAP1 host cell line is derived from the KBM-7 chronic myeloid leukemia line and maintains a near-haploid karyotype, which simplifies genetic manipulation and functional interpretation. As a hematopoietic model, HAP1 cells are extensively used in genetic screens, drug sensitivity profiling, and mechanistic studies of leukemia and programmed cell death, offering a physiologically relevant context for oncogenic signaling and apoptosis research.
BCL2 encodes an integral outer mitochondrial membrane protein that serves as a master regulator of the intrinsic apoptosis pathway. Its expression is transcriptionally induced by STAT3, NF-??B, and CREB downstream of PI3K/AKT and ERK signaling cascades, and is further promoted by cytokines such as IL-3 and IL-6. At the molecular level, BCL2 binds and neutralizes pro-apoptotic BCL2 family members including BAX, BAK, BAD, BID, BIM, PUMA, and NOXA, preventing their oligomerization and subsequent mitochondrial outer membrane permeabilization. This blockade maintains mitochondrial integrity, suppresses cytochrome c release, and inhibits apoptosome formation involving APAF1 and caspase-9, thereby blocking activation of executioner caspase-3.
Disruption of BCL2 in HAP1 polyclonal cells eliminates this anti-apoptotic barrier, sensitizing the near-haploid leukemia cells to intrinsic apoptotic stimuli. In the absence of functional BCL2, pro-apoptotic effectors such as BAX and BAK are de-repressed, triggering mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-3-mediated cell death. This genetically defined model recapitulates the pharmacologic action of BH3 mimetics and enables dissection of apoptosis signaling dynamics in a hematopoietic background, facilitating studies of oncogenic addiction to BCL2 and mechanisms of resistance.
This polyclonal knockout population is ideally suited for apoptosis research, cancer drug resistance studies, functional genomics screening, and validation of BH3 mimetics. Representative assays include western blotting for BCL2 loss and cleaved caspase-3, Annexin V/PI flow cytometry for apoptosis quantification, MTT or resazurin-based viability assays, cytochrome c release measurements, and BH3 profiling to assess mitochondrial priming. For additional technical information or custom applications, please contact Ascent Research.
